Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
CARBIDOPA, LEVODOPA
Accord Healthcare Limited
N04BA02
CARBIDOPA, LEVODOPA
50/200 Milligram
Tablet Prolonged Release
Product subject to prescription which may be renewed (B)
Dopa and dopa derivatives
Authorised
2013-02-01
PACKAGE LEAFLET: INFORMATION FOR THE USER APODESPAN PR 50 MG/200 MG PROLONGED RELEASE TABLETS CARBIDOPA AND LEVODOPA - Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their sign of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. WHAT APODESPAN PR ARE AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE APODESPAN PR 3. HOW TO TAKE APODESPAN PR 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE APODESPAN PR 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. WHAT APODESPAN PR ARE AND WHAT IT IS USED FOR Apodespan PR are used in the treatment of Parkinson‟s disease. It reduces the “off” time (a sudden onset of muscle stiffness that can last for minutes or even hours) if you are being treated with levodopa alone, levodopa/decarboxylase inhibitor tablets with an immediate-release formulation (e.g. carbidopa) and if you suffer from sudden uncontrolled movements. Apodespan PR belongs to a class of drugs used to treat Parkinson‟s disease. The symptoms of this disease are probably caused by a lack of dopamine, a substance that is normally produced by the brain. Dopamine plays a role in controlling muscle movement. A lack of it causes problems in muscle movement. Levodopa compensates for the lack of dopamine, Perskaitykite visą dokumentą
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Apodespan PR 50 mg/200 mg Prolonged-Release Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release tablet contains 50 mg of Carbidopa and 200 mg of Levodopa Excipient with known effect: Lactose monohydrate (24.00 mg) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged Release Tablet Peach to light peach colored with mosaic appearance, oval shaped, biconvex tablets of approximately 13.0 mm in length and approximately 7.0 mm in width debossed with ‘L200’on one side and plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Idiopathic Parkinson's disease, in particular to shorten the “off” period in patients who have previously been treated with immediate-release levodopa/decarboxylase inhibitors, or with just levodopa who showed motor fluctuations. Experience with Apodespan PR is limited in patients, who have not been previously treated with levodopa. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The daily dosage of Apodespan PR should be carefully determined. Patients should be monitored closely during the period of dose adjustment, especially with regard to the occurrence or exacerbation of nausea and abnormal involuntary movements such as dyskinesia, chorea and dystonia. Blepharospasm could be an early sign of overdosing. The pharmacokinetic properties of the prolonged-release tablets may be altered if the tablets are broken or chewed. Therefore the tablets must be swallowed whole. Most other medicines, used to treat Parkinson´s Disease, except for levodopa, can be continued during administration of Apodespan PR. However their dosage may need to be adjusted. Sudden withdrawal of Levodopa therapy should be avoided wherever possible. Since carbido Perskaitykite visą dokumentą